Wyeth selects novel drug targets in osteoporosis collaboration with Galapagos Genomics NV
"We are excited that we have successfully delivered on our commitments in our osteoporosis program with Wyeth. The selection of these targets is a critical decision as it forms the basis for the development of novel medicines," said Onno van de Stolpe, CEO of Galapagos. "The milestone by Wyeth underlines the power of the SilenceSelect platform as a powerful tool to discover novel drug targets and confirms the strength of our discovery biology research team in osteoporosis".
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.